Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01187979
Other study ID # CAPRISA 007
Secondary ID
Status Completed
Phase Phase 2
First received August 12, 2010
Last updated January 18, 2017
Start date September 2010
Est. completion date August 2014

Study information

Verified date January 2017
Source Centre for the AIDS Programme of Research in South Africa
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to assess the impact of a cash-incentivised prevention intervention on reducing HIV incidence rates in high-school learners in rural KwaZulu-Natal.


Description:

The impact of the cash incentivised intervention will be assessed using a matched pair, cluster randomised controlled trial design. The 14 selected high schools in the Vulindlela School Circuit will be matched in pairs. The matched pairs of schools will be the unit of randomisation. Baseline measurements, using a standardised tool (structured questionnaire and biological specimens) will be undertaken simultaneously in each matched pair and will include all eligibly enrolled and consenting learners in the respective schools. On completion of baseline measurements in each matched pair of schools, the randomisation code for the pair will be revealed and the intervention will be implemented in the intervention school. All schools will receive the same prevention intervention but only the intervention school will receive the cash incentives. Follow-up measurements will be undertaken approximately 12 and 24 months after implementation of the intervention using a similar standardised assessment tool to that used at baseline. At baseline and during follow-up assessments in intervention and control schools, linked HIV and substance use testing will be undertaken in all learners and pregnancy testing in female learners. Other secondary endpoints will be assessed using a structured questionnaire.


Recruitment information / eligibility

Status Completed
Enrollment 3217
Est. completion date August 2014
Est. primary completion date August 2014
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 13 Years and older
Eligibility Inclusion Criteria:

Learners must meet all of the following criteria at enrolment in order to be eligible for inclusion in the study:

- Male or female learner in Grade 9 or 10 in one of the 14 selected schools

- Willing and able to provide informed consent and/or assent to participate in the study

- Willing to provide locator data for home visits if necessary

- Not planning to move to another school or relocate in the next 36 months

- Willing to be finger-printed to verify identity for study procedure purposes

- Willing to participate in this study

- Willing to complete all study procedures

Exclusion Criteria:

- Refusal by the learner and/or parent or legal guardian to participate in the study.

- Unable to provide necessary informed consents

- Cognitively challenged learners

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Cash incentives
Cash incentives paid to learners for reaching pre-determined milestones
Life skills curriculum
Standard department of education lifeskills curriculum

Locations

Country Name City State
South Africa Vulindlela Clinical Research Site Durban KwaZulu-Natal

Sponsors (4)

Lead Sponsor Collaborator
Centre for the AIDS Programme of Research in South Africa Embassy of the Kingdom of the Netherlands (EKN), KwaZulu-Natal Department of Education, MIET Africa

Country where clinical trial is conducted

South Africa, 

References & Publications (3)

Fernald LC, Hou X, Gertler PJ. Oportunidades program participation and body mass index, blood pressure, and self-reported health in Mexican adults. Prev Chronic Dis. 2008 Jul;5(3):A81. — View Citation

Hargreaves JR, Glynn JR. Educational attainment and HIV-1 infection in developing countries: a systematic review. Trop Med Int Health. 2002 Jun;7(6):489-98. Review. — View Citation

Pettifor AE, Rees HV, Kleinschmidt I, Steffenson AE, MacPhail C, Hlongwa-Madikizela L, Vermaak K, Padian NS. Young people's sexual health in South Africa: HIV prevalence and sexual behaviors from a nationally representative household survey. AIDS. 2005 Sep 23;19(14):1525-34. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary HIV-incidence rates To evaluate the efficacy of a cash-incentivised prevention intervention in reducing HIV-incidence rates in high-school learners annually, after every 12 months of follow up
Secondary Academic performance measured as an overall passing grade (50%) To support learners improving academic performance, attend school, complete schooling and improve their self-esteem, learners will be incentivised to pass their June and November examinations, with a minimum of a 50% average. Educators from the selected schools will design, administer and mark the June and November examination papers. 6 monthly
Secondary voluntary uptake of HIV testing Learners must provide the receipt from the clinic that specifies that the learner was tested for HIV. annually, after every 12 months of follow up
Secondary Substance use patterns Urine specimens will be utilised for testing for the presence of recreational drugs. annually, after every 12 months of follow up
Secondary Pregnancy rates in female learners A dipstick pregnancy test will be performed on the urine sample of all female learners at baseline and at the two annual follow-up visits. annually, after every 12 months of follow up
Secondary Contraceptive use patterns in female learners Annual behavioural questionnaires will monitor self-reported contraceptive use. annually, after every 12 months of follow up
Secondary Participation in extra-curricular activities Attendance and participation in a life skills/sustainable livelihoods programme will be assessed. Self-reported participation in extra-curricular activities will be assessed in annual behavioural questionnaires. annually, after every 12 months of follow up
Secondary HIV risk reduction behaviour The following will be assessed through a self-reported questionnaire:
condom use; primary and/or secondary sexual abstinence rates; sexually transmitted disease rates intergenerational sexual coupling (age of sexual partner(s)) age of sexual debut; frequency of HIV testing; number of concurrent sex partners; frequency of partner change; medical male circumcision rates; anal sex rates
Annually, after every 12 months of follow up
See also
  Status Clinical Trial Phase
Completed NCT05454514 - Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS N/A
Completed NCT03760458 - The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age Phase 1/Phase 2
Completed NCT03067285 - A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study Phase 4
Completed NCT03141918 - Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS N/A
Recruiting NCT04579146 - Coronary Artery Disease (CAD) in Patients HIV-infected
Completed NCT06212531 - Papuan Indigenous Model of Male Circumcision N/A
Active, not recruiting NCT03256422 - Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients Phase 3
Completed NCT03256435 - Retention in PrEP Care for African American MSM in Mississippi N/A
Completed NCT00517803 - Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies N/A
Active, not recruiting NCT03572335 - Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
Completed NCT04165200 - Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV N/A
Recruiting NCT03854630 - Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection Phase 4
Terminated NCT03275571 - HIV, Computerized Depression Therapy & Cognition N/A
Completed NCT02234882 - Study on Pharmacokinetics Phase 1
Completed NCT01618305 - Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission Phase 4
Recruiting NCT05043129 - Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
Not yet recruiting NCT06072443 - AURORA Study-A Transformative Approach to Support PrEP Medication Persistence
Not yet recruiting NCT05536466 - The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine N/A
Recruiting NCT04985760 - Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy Phase 1
Completed NCT05916989 - Stimulant Use and Methylation in HIV

External Links